Hypertrophic Cardiomyopathy

Resource Page for Professionals

Hypertrophic cardiomyopathy or HCM is a primary myocardial disorder defined by left ventricular (LV) hypertrophy that cannot be explained by another cardiac or systemic disease. People with HCM face a risk of death more than 3 times greater than the average person of the same age without HCM.

Patients diagnosed with HCM are at increased risk for developing atrial fibrillation, suffering from stroke and even sudden cardiac arrest. It is estimated that 1 in every 500 people have HCM, but a large percentage of patients are undiagnosed. Learning more about HCM will ensure you are better able to discuss its impact with your patients.

Patients with HCM

Some people with HCM experience symptoms such as fatigue, fainting, shortness of breath, chest pain or abnormal heart rhythms known as arrhythmias. Others with HCM do not experience any symptoms. When a patient presents with common symptoms not attributed to known conditions – shortness of breath, chest pains, arrhythmias or fainting – consider checking for hypertrophic cardiomyopathy.

HCM is a chronic disease that can progress to the point at which patients develop cardiac dysfunction and clinical syndrome of heart failure. People with HCM face a risk of death more than 3 times greater than the average person of the same age without HCM.

Those with HCM are at increased risk for developing atrial fibrillation, suffering from stroke and even sudden cardiac arrest. It has been cited as the most common reason for cardiovascular sudden death in young people and athletes.

HCM Webinar Series

The HCM Education Webinar Series will address knowledge gaps, the needs and challenges of at-risk populations, emerging treatments and other factors that contribute to improved care and outcomes for patients with Hypertrophic Cardiomyopathy.

Hypertrophic Cardiomyopathy: An Introduction and Overview

Learn more about HCM in this free recorded webinar so you are better able to discuss its impact with your patients. 

Join leading James E. Udelson, MD, FAHA, Chief, Division of Cardiology, Tufts Medical Center, Sharon Cresci, MD, FAHA, FACC, FASE, Associate Professor of Medicine, Associate Professor of Genetics, Washington University, Cardiovascular Division, and Robert J. Fraser, MD, Chief Cardiology Fellow, Hennepin Healthcare and Minneapolis Heart Institute, as they explore the HCM symptoms, epidemiology, pathophysiology and the burden of the disease on patients and families.


American Heart Association's Hypertrophic Cardiomyopathy Initiative is sponsored by MyoKardia, Inc.